It is important to know and decide when to end regimen for the quality of life of the patients. However, there is currently no clear agreement on when to terminate palliative chemotherapy. We investigated the duration between the last chemotherapy and death, and associated factors aff ecting patients receiving palliative care after the last chemotherapy.
INTRODUCTION
Th e incidence of cancer in Korea has increased 3% per year from 1999 to 2007. About 160,000 new cancer cases occur every year and mortality rate exceeds 140 per 100,000 people. 1) Due to ongoing development of new 'less toxic thus well tolerated' drugs, anti-cancer chemotherapy until the end-of-life is gradually increasing. 2) However, an excessive chemotherapy can decrease patients in the palliative care ward; whether to enforce appropriate chemotherapy in a purpose of treating patients in palliative care ward need to be discussed. 3, 4) Thus it is important to know and decide when to end regimen for the quality of life of the patients. However, there is currently no clear agreement on when to terminate palliative chemotherapy. We therefore investigated the duration between the last chemotherapy and death, and associated factors aff ecting patients receiving palliative care aft er the last chemotherapy.
METHODS

Subjects
Subjects of this study are 309 patients who died during hospitalization in the palliative care ward in Samsung Medical
Center from January 1, 2008 to May 31, 2009. Among these patients, 67 patients were excluded due to following reasons:
2 patients were non-cancer terminal illness, 62 patients never received anti-cancer chemotherapy since diagnosis of cancer and 3 patents has been initially registered in the palliative care ward then re-treated with anti-cancer chemotherapy. Thus electronic medical records of 242 patients have been studied in this investigation. These patients had been treated with anti-cancer chemotherapy more than once before referral to palliative care unit. 
Data Collection
RESULTS
Baseline Characteristics of Study Subjects
Mean age of the study subjects was 58.5 (± 12.5) years.
Median days from the end of chemotherapy to registration of palliative care were 64.5 days. Survival time after registration in palliative care was 17.5 days and survival time after the end of chemotherapy was 103 days. There were significant diff erences between male and female in the number of palliative chemotherapy regimen, level of education, and religion.
However there were no significant differences between male and female in length of palliative chemotherapy, period from the end of chemotherapy to the date of registration in palliative care, ECOG performance at the time of registration in palliative care, survival time aft er the end of chemotherapy and length of survival after registration in palliative care. The highest number of patients suffered from gastrointestinal cancers including colorectal and stomach, which were 104 patients (43%), followed by 37 lung cancer patients (15.3%), 27 hepatobilliary cancer patients (11.2%) and 26 pancreatic cancer patients (10.7%) ( Table 2 ). This finding suggested that the patients having more survival duration had a relatively bett er performance status, but there were no signifi cant within one month before death, compared with the other study showing up to 20% of patients did so within 2 weeks before death. 9) This difference may be explained by the fact that our patients were referred to palliative care center thus treated less aggressively, 7, 10) but the patients from other studies might not have an access to palliative care. We found that the patients referred to palliative care had few futile chemotherapy near the end of life.
However, it remains to be confirmed whether this finding had some impact on improved survival or quality of life of patients.
Th e previous studies showed various relationships between patient's factors and persistent chemotherapy near the end of life and differed by socio-cultural conditions. Patients who were older, female, and had an access to palliative care, received less aggressive chemotherapy.
2) Married patients received less aggressive chemotherapy than unmarried patients. 5) Patients who were younger and had chemotherapy-sensitive tumors such as gastrointestinal cancer, received more aggressive chemotherapy.
However, men rather than women received less aggressive chemotherapy. 6) Patients, who were symptomatic, under the age of 45 and were not referred to palliative care, were likely to continue receiving chemotherapy. 10) College graduate chose less aggressive treatment near the end of life in a study carried out in Korea, 7) but there were no relationship between educational level and choice of chemotherapy in terminally ill cancer patients in a study done in Netherlands.
11)
In this study, we could not find any association between chemotherapy near the end of life and many patient factors such as age, sex, religion, level of education, site of cancer and sociodemographic factors only except performance status at the time of registration in palliative care. This could be explained by a small sample size. There were only 14 patients who underwent chemotherapy during the last month of life and the number of events was too small to find the related factors. Another explanation is that the patients of our study already opted for palliative care. Selection of palliative care can be a strong factor to deny chemotherapy near the end of life. It is also consistent with a previous study on patients with metastatic cancer, which showed that patients considering a quality of life were likely to receive fewer chemotherapy and gett ing chemotherapy had no signifi cant association with gender, age, and level of education.
We could not analyze the effect of physician factors on chemotherapy near the end of life, but the role of physician is important in doing aggressive chemotherapy until the end of life in Korea, considering that referral to palliative care is mostly done when there are no further chemotherapy options available. 12) One study reported that doctors felt uncomfortable in offering palliative care to advanced cancer patients but felt easier in discussing another chemotherapy options. 13 ) Also a study on 95 incurable advanced cancer patients showed that only 39%
of patients were told of their prognosis by their physician even though they were already getting palliative chemotherapy. 14) As physician's lack of eff ort to communicate with patients can cause futile chemotherapy near the end of life, further study is needed on the association of physician factors with chemotherapy near the end of life.
It is difficult to generalize our findings as this was a retrospective study conducted at a single tertiary hospital.
Another limitation of this study is that impact of chemotherapy near the end of life on the quality of life cannot be evaluated directly. However, several studies have already reported that there was more harm in doing chemotherapy near the end of life. 3,4) Also we could not obtain objective data on purpose and effectiveness of palliative chemotherapy as wells as reason for starting or continuation of chemotherapy, thus it was impossible to assess whether the chemotherapy were appropriate or excessive.
Nevertheless, this study has advantages as it examined patients receiving palliative care and discussed differences with other existing studies. The existing studies reported that availability of palliative care 2) or providing information on palliative care 10) played an important role in patient's decisionmaking on treatment and reduced likelihood of receiving aggressive chemotherapy. Th us it is thought to be meaningful to find out current situation of chemotherapy near the end of life among the patients at palliative care unit.
In conclusion, authors found there was no difference on administration of chemotherapy within 3 months before death between palliative care group in this study and usual care
group from other studies. However, less chemotherapy were administered to the patients within one month before death in 
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